Concord Drugs Q3 Results
- BSE: 538965
- NSE: -
- ISIN: INE858L01010
- Sector: Biotechnology & Drugs
BSE
71.73
-2.19 (-2.96%)
-2.19 (-2.96%)Volume6.00 K
Updated: Fri 13 Mar, 2026 | 15:26:59
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹16.97 Cr.(57.10%)
- Operating Profit₹0.61 Cr.(-39.97%)
- Profit After Tax₹0.22 Cr.(-4.32%)
- Operating Margin3.62%(-61.79%)
Note: Comparison is on YoY basis
Quarterly - Concord Drugs Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 16.35 | 11.84 | 71.78% | 12.54 | 67.27% |
| Depreciation/ Amortization | 0.31 | 0.34 | -9.63% | 0.39 | -17.20% |
| Operating Income | 0.61 | 0.52 | -18.80% | 0.24 | -39.97% |
| Net Income | 0.22 | 0.04 | 12.73% | -0.24 | -4.32% |
| Other Operating Expenses Total | 0.42 | 0.41 | 13.58% | 0.49 | 64.92% |
| Net Income Before Taxes | 0.30 | 0.07 | 9.14% | -0.26 | -43.80% |
| Total Revenue | 16.97 | 12.36 | 65.10% | 12.78 | 57.10% |
| Selling/ General/ Admin Expenses Total | 1.24 | 0.93 | 13.04% | 1.54 | 23.21% |
| Diluted Normalized EPS | 0.16 | 0.04 | -15.79% | -0.24 | -30.43% |